Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

VLDL metabolism

  • Home
  • VLDL metabolism
Dapagliflozin and Lipoprotein Metabolism in Type 2 Diabetes: Preserving LDL Catabolism and Normalizing VLDL Processing
Posted inCardiology Diabetes & Endocrinology news

Dapagliflozin and Lipoprotein Metabolism in Type 2 Diabetes: Preserving LDL Catabolism and Normalizing VLDL Processing

Posted by MedXY By MedXY 07/31/2026
This study demonstrates that dapagliflozin does not impair LDL catabolism but favorably shifts VLDL1 and VLDL2 catabolism toward normal physiology in type 2 diabetes, potentially contributing to reduced atherosclerosis risk.
Read More
  • Rethinking Placenta Accreta Spectrum: A Topography-Guided Approach to Prenatal Imaging and Tailored Surgical Management
  • Disparities and Persistence in Systemic Hormone Therapy Among Menopausal Women: Insights from a Large Real-World Analysis
  • RIPPLY1 as a Guardian Against Cancer Stemness in CTNNB1-Mutated Hepatocellular Carcinoma
  • Proteomic Insights into MASLD: Sex-Specific Endotypes and Predictive Value for Mortality
  • Revolutionizing Stage II Colorectal Cancer Prognostication: Validating Semantically-Enhanced AI for Risk Stratification
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in